Physician profile
Sharan Parikh
NPI 1154859205
$3,112.37
in general payments reported to CMS, 2019-2025
32 companies · $802 in 2025
The $802 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $169 · 2021: $696 · 2022: $381 · 2023: $452 · 2024: $612 · 2025: $802.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,866.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,865.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $491.91 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $320.72 | 2020-2021 | |
| Dexcom, INC. | $256.63 | 2021-2025 | Dexcom G6 Transmitter |
| Horizon Therapeutics Plc | $225.04 | 2022-2023 | Tepezza |
| Amgen INC. | $164.91 | 2022-2025 | Tepezza, Evenity, Prolia |
| Insulet Corporation | $163.98 | 2021-2025 | Omnipod |
| Alexion Pharmaceuticals, INC. | $139.40 | 2022-2025 | Strensiq |
| Sanofi-Aventis U.S. LLC | $137.08 | 2024-2025 | |
| Zealand Pharma US, INC. | $114.83 | 2021 | |
| Cequr Corporation | $112.51 | 2023-2025 | Cequr Simplicity |
| Lilly USA, LLC | $108.79 | 2022-2025 | Mounjaro, Zepbound |
| Xeris Pharmaceuticals, INC. | $107.52 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Mannkind Corporation | $100.38 | 2021 | |
| Tandem Diabetes Care, INC. | $94.75 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amryt Pharma Holdings LTD | $87.57 | 2022-2023 | Mycapssa |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $74.40 | 2022-2025 | |
| Ascendis Pharma Endocrinology INC | $58.91 | 2023-2025 | Yorvipath |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.65 | 2022-2024 | Jardiance |
| Corcept Therapeutics | $45.36 | 2023-2024 | Korlym |
| Neurocrine Biosciences, INC. | $43.41 | 2025 | |
| Sequel Med Tech, LLC | $23.40 | 2025 | Twiist |
| Rgh Enterprises LLC | $22.46 | 2025 | |
| Halozyme INC | $22.19 | 2023 | |
| Abbott Laboratories | $21.46 | 2022 | |
| Embecta Corp. | $18.65 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Ionis Pharmaceuticals, INC. | $17.35 | 2025 | Tryngolza |
| Madrigal Pharmaceuticals | $16.53 | 2025 | Rezdiffra |
| Merck Sharp & Dohme LLC | $16.36 | 2023 | Verquvo, Segluromet, Steglatro |
| Ibsa Pharma INC. | $14.98 | 2022 | |
| Abbvie INC. | $14.93 | 2024 | |
| Amneal Pharmaceuticals LLC | $14.10 | 2023 | Unithroid |
| Amphastar Pharmaceuticals, INC. | $13.21 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharan Parikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.